Growing Prevalence of Cough is Boosting the Cough Remedies Market

The global cough remedies market is anticipated to grow at a CAGR of 4.1% during the forecast period (2024-2031). The market growth is driven by the growing prevalence of cough and flu. Further, a switch from prescription to OTC category, a rise in the geriatric population, and demand for effective combination products are anticipated to drive the market. However, competition faced by international players and natural remedies restrain the market growth. The global cough remedies market is segmented by product type (antihistamine, expectorant, bronchodilator, decongestant, and antibiotic), by dosage form (oral syrup, tablet/pills, nasal drop, and lozenge), and by geography (into North America, Europe, Asia-Pacific, and Latin America and the Middle East and Africa).

Browse the full report description of “Global Cough Remedies Market Size, Share & Trends Analysis Report, By Product Type (Antihistamine, Expectorant, Bronchodilator, Decongestant, and Antibiotic), By Dosage Form (Oral Syrup, Tablet/Pills, Nasal Drop, and Lozenge), Forecast (2024-2031)” at https://www.omrglobal.com/industry-reports/cough-remedies-market

The oral syrup segment is anticipated to hold the major market share during the forecast period, owing to the ease of administration, across age groups. Additionally, syrups treat a variety of symptoms such as cough, sore throat, and nasal congestion, contributing considerably to the segmental dominance.

The expectorants segment is expected to gain the highest CAGR during the forecast period, owing to the surge in incidences of respiratory diseases such as pneumonia, chronic obstructive pulmonary syndrome, and other infectious diseases that can cause congestion in the lungs and create cough in the chest walls. Additionally, expectorants remove dry cough from the chest wall easily, thus, a rise in the incidence of dry cough is expected to propel the market growth.     

The major players in the global cough remedies market include Pfizer Inc., Johnson & Johnson Services, Inc., and GlaxoSmithKline plc, among others. The market players are contributing significantly to the market growth by the adoption of various business strategies, such as product development, mergers and acquisitions, partnerships, and more.  

Recent Developments 

• In December 2023, the US Food and Drug Administration (FDA) declined to approve Merck's drug for chronic cough. The company's application for the drug, gefapixant did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic cough.

• In September 2023, Genexa introduced new clean Over-the-counter (OTC) kids’ medicine. The Kids’ Multi-Symptom Cold & Flu and Kids’ Daytime + Nighttime Cough Relief Value Pack provide the OTC options with the same effective active ingredients without any dyes and artificial sweeteners, parabens, or common allergens. The product is made from organic agave syrup. 

• In June 2023, GSK Plc acquired Bellus Health Inc. for $2 billion. The UK drugmaker will pay $14.75 per share. The acquisition is aimed at replenishing the product pipeline and gaining cough medicine. 

• In May 2023, Hyfe, Inc., expanded into chronic cough treatment with digital therapeutics.

• In November 2022, Genexa launched Cough & Chest Congestion medicines for adults. The product is designed to temporarily control cough, relieve chest congestion, and help thin and loosen mucus. It delivers the same active ingredients as Mucinex® Fast-Max DM, without artificial inactive ingredients such as sorbitol, FD&C red 40, sucralose, and more. 

• In May 2022, Procter & Gamble India’s cough and cold brand Vicks launched Vicks Tulsi Cough Drops in India. 

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cough-remedies-market